2nd-generation drug-eluting stents, results for “real” patients at two years

Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press.

 

In recent years there have been new drug-eluting stents in order to minimize the main drawbacks of 1st generation stents such as restenosis, thrombosis and the consequent need for target vessel revascularization. The aim of this study was to compare the efficacy and safety of two second-generation stents, the RESOLUTE zotarolimus-eluting stent (ZES) and the everolimus-eluting stent Xience V (EES).

The novelty of this work is that the authors chose a patient population that closely resembles real life, with virtually no exclusion criteria, (only patients with ST elevation AMI admitted, were excluded), with follow-up at two years and a strict suspension of dual antiplatelet therapy after a year of the procedure. A total of 1,391 patients were randomized in a 1:1 ratio to receive treatment with either Resolute ZES (n = 697) or Xience V EES (n = 694). The primary endpoint was established as cardiovascular death, myocardial infarction related to the target vessel or target vessel revascularization. At this point there were no significant differences between the two groups analyzed, (10.8% versus 11.6%, p = .65). Also evaluated as secondary endpoints were definitive, probable or very late thrombosis. The results were similar for both groups with no significant differences and encouragingly low rates, (0.9% versus 0.1%, p = 0.12), (1.2% versus 1.4%, p = 0.63) and (0.3% vs 0.3%, p = 1 ) respectively. These results were consistent across all the subgroups analyzed.

Conclusion: 

Considering that the percentage of patients who continued dual antiplatelet therapy beyond one year was as low as 5.4% of the patients randomized, this study shows that the use of second generation drug-eluting stents is effective and safe with no clinically relevant differences between the two stents studied, even after discontinuation of dual antiplatelet therapy.

Commentary: 

This work provides useful information because it was conducted in a population selected with out specific requirements, regardless of the length, morphology or the number of lesions, including off-label patients with indications for implantation of drug-eluting stents. It gives us results much more akin to what happens in real life than usually found in classical studies. The results are encouraging, since they show a very low rate of thrombosis and infarction that are generally most feared events when using these stents to treat vessels. So again, this is good news for interventional cardiologists. Although we have to keep in mind that this is not applicable to patients with ST elevation AMI. 

Courtesy Dra. María Sol Andrés.
University Hospital Favaloro Foundation – Argentina.

Dra. María Sol Andrés para SOLACI.ORG

More articles by this author

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...